NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners.
NFL Biosciences obtained a €600,000 'Innovation Advance' repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate.
This €1.2 million adds to the €3.0 million raised in the oversubscribed capital increase at the end of May 2025. The company also expects to secure additional non-dilutive funding and plans to benefit each year from the reimbursement of a portion of its R&D expenses through the Research Tax Credit. These funds are allocated to the continued development of NFL-101, its proprietary drug indicated for smoking cessation.
The company is currently engaged in scientific advice procedures with European regulatory authorities and the FDA. The feedback expected at the end of the summer will enable the company to confirm its development strategy, notably in relation to manufacturing, preclinical and clinical aspects.
'We would like to sincerely thank Bpifrance for its support, as well as our banking partners Société Générale and Banque Populaire du Sud. We have recently secured €4.2 million to support our development, and we are confidently approaching the launch of Phase 3. We are also continuing to seek additional non-dilutive funding and remain focused on rigorously managing our structural costs,' commented Bruno Lafont, Chief Executive Officer of NFL Biosciences.
About NFL Biosciences: www.nflbiosciences.com
NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on www.nflbiosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Retail ETFs Pop on EU Deal; MAGS, QQQ Rise Ahead of Earnings
Retail ETFs jumped on Monday as the United States clinched a trade deal with the European Union, setting tariffs at 15%. The deal comes just ahead of the Aug. 1 deadline the White House set for all tariff negotiations, refusing to extend or delay any further. Speaking alongside U.K. Prime Minister Keir Starmer, President Donald Trump explained that going forward, there would be a "global tariff" in the range of 15%-20%. Retail ETFs jumped on the news while broad markets also inched higher before paring gains. XRT Flatlines, VGK Drops The SPDR S&P Retail ETF (XRT) rose mildly in early trading Monday before falling by 0.5% midday. The ProShares Online Retail ETF (ONLN) fared much better, jumping nearly 1% before giving back some gains, boosted in part by tech darling Inc. (AMZN). The EU is the largest trading partner to the United States with major imports in the furniture, wine/alcohol, rubber and machinery categories. The $600 billion dollar deal would see the EU increase American energy and defense imports. The Vanguard FTSE Europe ETF (VGK) fell 1.9% as of midday Monday on the news. But despite the White House lauding the trade agreement as a "landmark deal," investors have set their sights on earnings and an upcoming Fed decision. MAGS Jumps Ahead of Major Tech Earnings Four members of the "Magnificent Seven"—Meta Platforms Inc. (META), Microsoft Corp. (MSFT), Apple Inc. (AAPL) and AMZN—are set to report quarterly earnings this week, turning investor interest to the tech sector. Markets are set to pay close attention to any news about artificial intelligence and investments into AI tech and strategies. The Roundhill Magnificent Seven ETF (MAGS) jumped Monday as investors were more attracted to risk ahead of earnings. The Invesco QQQ Trust (QQQ), which mirrors the tech-heavy Nasdaq-100 index, also notched gains. Invest in Gold Thor Metals Group: Best Overall Gold IRA Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase American Hartford Gold: #1 Precious Metals Dealer in the Nation Tech companies will have to clear a lower bar this quarter after analysts slashed estimates amid tariff concerns and the central bank holding rates steady. Last week, Alphabet Inc. (GOOGL) beat earnings expectations and raised spending forecasts. But Mag 7 member Tesla Inc. (TSLA) disappointed, pointing to slumping revenue and tougher margins. Tesla CEO Elon Musk told investors to brace for some rough quarters in the future. Fed Expected to Hold Rates Steady Rounding out a busy week ahead, the Federal Reserve is set to meet this week and make a decision on rates. According to the CME FedWatch Tool markets are pricing a 97% chance that the Fed will hold rates steady. A rate cut is largely not expected until the fall at the September FOMC meeting. Tariff concerns have continued to weigh on the central bank, which is currently walking a tightrope between economic stimulus and reigning in inflation. The impact of tariffs has yet to appear in inflation reports, causing the Fed to hold its course. During testimony last month in front of the House Financial Services Committee, Fed Chair Jerome Powell confirmed that the Fed would have cut rates by now were it not for tariffs. Bond yields rose Monday in advance of the Fed meeting, sending Treasury bond prices lower. Yields and prices move in opposite directions. The iShares 20+ Year Treasury Bond ETF (TLT) dipped 0.6% as of Monday | © Copyright 2025 All rights reserved Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
an hour ago
- USA Today
Lynch: The PGA Tour's new boss started work today. So what headache does he tackle first?
Brian Rolapp is so little-known that we can't hazard a guess whether he's the type to have brought along a desktop calendar of inspirational quotes for his first day on Monday as CEO of PGA Tour Enterprises. You know, boilerplate bullshit about new jobs being like blank books and that you, Brian, are its author. Or that old banality about doing the hard jobs first and the easy ones will take care of themselves. Chances are that even before he shouldered his backpack and headed off to the GloHo this morning, Rolapp understood that, for now at least, he's less the author of this book than its editor — tying up loose threads, trimming excess, erasing gaffes — and that his inbox doesn't actually contain many easy jobs. So other than booking a lesson package at the TPC Sawgrass Performance Center, what does Rolapp's priority list look like? Since he's not a product of the golf executive ecosystem — nor even really a golfer — he'll want to start forging relationships. He signaled as much in his first day social media post about being 'excited to listen and learn.' (Lesson One: it's a capital offense to wear apparel not emblazoned with Tour logos, so ditch the plain polo and get measured for your branded gear, though you should demur if Jay Monahan offers a local tailor recommendation). Who is Brian Rolapp? 5 things to know about the PGA Tour's new CEO There are plenty who will want his ear, but Rolapp should be selective in whose ear he wants. Start with meeting Jack Nicklaus to better understand the statutory obligations of his role that aren't explained by spreadsheets. Move on to stakeholders who need to be heard — sponsors, not least FedEx; tournament organizers; Tour members, current and veteran; broadcast partners; and the most important but least heeded constituency, the fans. These groups aren't always aligned in what changes they'd like to see, but time spent with each will help Rolapp grasp the fundamental chasm hurting his business. His partners all have the same end user in mind — the golf consumer — but Tour HQ prioritizes a different end user of its services: players. That gap has been woefully exposed in recent years and needs to be bridged. What undermines the ambitions of most CEOs (other than the kiss cam at a Coldplay concert) is a lack of investment capital to support their vision. Rolapp's dilemma, though, is a welcome one — how to deploy the $1.5 billion Strategic Sports Group poured into the PGA Tour 18 months ago. Not a dime of that money has been spent, and he will immediately be reviewing whatever proposals exist for its use and deciding on an investment strategy consistent with his goals. Some of that slush fund ought to be allocated to consolidating relations with the DP World Tour, building gradually toward a more global footprint, as Rolapp did at the NFL. The Tour's annual cash obligations to the European circuit are unpopular with the SSG investors, but he needs to balance the long-term health of the professional game against short-term balance sheet concerns. One of the more delicate challenges facing Rolapp is addressing the Tour's power imbalance. Some (but not all) players on the board think they are executives and some (but not all) investors fancy themselves day-to-day managers. Those two constituencies won't always agree on what is best for the Tour and neither can be trusted with ultimate power. The whiz kids of Greater Fenway think they wield it because they sign the checks, while players believe they're in control because they have the board votes. Rolapp needs to reassert executive function at headquarters, an authority that was diminished when Monahan signed the Framework Agreement and thereafter had to constantly placate his members. Attention will predictably focus, however, on how the new boss navigates the quagmire that bogged down the old boss. Talks with the Public Investment Fund of Saudi Arabia are non-existent, and the deal outlined in the Framework accord is not close to consummation, thanks to Saudi intransigence, rampant ambivalence among Tour players, and the obvious fact that any deal would involve compromising the PGA Tour product simply to save the blushes of LIV's underwriter, Yasir Al-Rumayyan. While negotiations are seen as ongoing, there will continue to be a perception that the Tour is missing a critical element that only LIV can provide, which isn't true. If Rolapp wants to emphasize his organization's momentum and flip the narrative to innovation and progress, he should cut bait and sail on. A good faith effort has yielded nothing for two years. Stop treating LIV like a serious threat and dismiss it with the derision it deserves. 'Uncertainty's not good for anybody,' said Roger Goodell, Rolapp's old boss at the NFL. As inspirational quotes go, it makes up in simplicity what it lacks in sentimentality. Still, it's not a bad one to start a work day with.
The Hill
an hour ago
- The Hill
Trade tensions loom ahead of Friday deadline
Talks between the U.S. and China are starting in Stockholm, Sweden, and Trump and U.K. Prime Minister Keir Starmer are in Scotland fleshing out the U.K. trade deal that was announced earlier this year. Trump's Aug. 1 deadline for the resumption of tariffs is fast approaching, though China and the U.S. are facing an Aug. 12 deadline following agreements announced in May and June that brought down mutually imposed triple-digit tariffs. The White House announced a trade deal with the European Union on Sunday that will see the EU purchase U.S. fossil fuels. European leaders are criticizing the deal. 'It's a dark day when an alliance of free peoples — who are joined to affirm their values and defend their interests — resolve to submit,' French Prime Minister Francois Bayrou said. Trump has threatened to impose tariffs on any other country that doesn't make a trade deal before Friday, suggesting Monday that that rate would be around 15 percent to 20 percent. 'We're going to be setting a tariff for essentially the rest of the world, and that's what they're going to pay if they want to do business in the United States. Because you can't sit down and do 200 deals. But we made the big ones,' he said. The White House has also insisted it would hold the Aug. 1 deadline, while previous deadlines for tariffs have moved since April.
